Workshop Session 3B: In Quest for Common Ground for Addiction Medications: FDA-approved and Emerging Pharmacotherapies

In this workshop the current FDA-approved medications for substance use disorders (Opioid Use Disorder, Alcohol Use Disorder, and Tobacco Use Disorder) will briefly be reviewed. An overview of emerging pharmacotherapies for substance use disorders (SUD) will also be discussed with a focus on the developing evidence-base for these novel treatments, including psychedelics for SUD and mental health conditions. Following the lightening round review of current and evolving psychotherapeutics, the presenters will lead a deep-dive into the use of medications as an evidence-based approach to the treatment of Opioid Use Disorder (OUD). Despite several decades of clinical research evidence, the use of medications for opioid use disorder (MOUD) has not been broadly adopted by specialty substance use disorder treatment programs. This workshop will cover several central biases that are often related to less utilization of medications, and a framework of how to integrate medications into an integrated approach to care will be presented.